This concept is delineated in the study by Siam et al., 2021 (41), where they evaluated the efficacy of two CYP inhibitors to be repurposed as an Akt pathway inhibitor in the treatment of oral cancer. The gene discussed is AKT1; the disease is lip and oral cavity carcinoma.